HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Jedrzejczak-Czechowicz Selected Research

Atopic Dermatitis (Atopic Eczema)

1/2018Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Jedrzejczak-Czechowicz Research Topics

Disease

5Hypersensitivity (Allergy)
01/2018 - 07/2008
3Asthma (Bronchial Asthma)
01/2017 - 09/2010
2Anaphylaxis (Anaphylactic Shock)
01/2017 - 06/2015
2Polyps
01/2011 - 09/2010
2Nasal Polyps (Nasal Polyp)
01/2011 - 09/2010
1Seasonal Allergic Rhinitis (Hay Fever)
01/2018
1Atopic Dermatitis (Atopic Eczema)
01/2018
1Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
01/2017
1Eye Diseases (Eye Disease)
01/2017
1Urticaria (Hives)
01/2017
1Food Hypersensitivity (Food Allergy)
05/2015
1Rhinosinusitis
01/2011
1Inflammation (Inflammations)
01/2011

Drug/Important Bio-Agent (IBA)

3AllergensIBA
01/2018 - 05/2015
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2011 - 07/2008
2Immunoglobulin E (IgE)IBA
01/2018 - 01/2017
2Arachidonic Acid (Vitamin F)IBA
01/2011 - 07/2008
2AcidsIBA
01/2011 - 07/2008
1Epinephrine (Adrenaline)FDA LinkGeneric
06/2015
1Complement System Proteins (Complement)IBA
05/2015
115-hydroxy-5,8,11,13-eicosatetraenoic acidIBA
01/2011
1Misoprostol (Cytotec)FDA LinkGeneric
01/2011
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2010
1Interleukin-2 (IL2)IBA
09/2010
1Interleukin-4 (Interleukin 4)IBA
09/2010
1Interleukin-5 (Interleukin 5)IBA
09/2010
1SuperantigensIBA
09/2010
1Enterotoxins (Enterotoxin)IBA
09/2010
1Messenger RNA (mRNA)IBA
09/2010

Therapy/Procedure

1Contraindications
01/2017